<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134413">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01810679</url>
  </required_header>
  <id_info>
    <org_study_id>G120053</org_study_id>
    <nct_id>NCT01810679</nct_id>
  </id_info>
  <brief_title>Perceval S Aortic Heart Valve Study- North America</brief_title>
  <official_title>Clinical Investigation of the Perceval S Sutureless Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorin Group USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorin Group USA, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and effectiveness of the Perceval S heart valve when used to
      replace a diseased or dysfunctional aortic valve or aortic valve prosthesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigation is a prospective, non-randomized, multi-center trial of the PERCEVAL
      valve implanted in patients requiring aortic valve replacement.  The study will be conducted
      in a maximum of 25 centers in the United States.  Patients will be evaluated at each of the
      following time intervals:preoperative, at implant, in the early postoperative period, in the
      late postoperative period (between 3 and 6 months postoperatively), at 1 year (between 11
      and 13 months postoperatively), and annually until study completion.  The duration of the
      study is anticipated to be 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>One-year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To demonstrate that the complication and survival rates for the PERCEVAL S valve are comparable to appropriate historical controls manifested as objective performance criteria (OPCs) and to that reported for other stented bioprostheses in the literature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>One-year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate that the rate of valve success for the PERCEVAL S valve is comparable to that of appropriate historical controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcomes</measure>
    <time_frame>One-year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate that the hemodynamic performance of the PERCEVAL S valve is comparable to that reported in the literature for other stented aortic bioprostheses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcomes</measure>
    <time_frame>One-year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate clinically significant improvements in overall patient condition by comparison of preoperative and postoperative NYHA functional classifications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcomes</measure>
    <time_frame>One-year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate that the rate of device technical success for the PERCEVAL S valve is comparable to that of appropriate historical controls</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Supplementary Analyses</measure>
    <time_frame>Discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rates of cross-clamp time, cardiopulmonary bypass time, length of stay in ICU, length of hospital, and quality of life</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Stenosis With Insufficiency</condition>
  <condition>Regurgitation, Aortic Valve</condition>
  <condition>Aortic Valve Incompetence</condition>
  <arm_group>
    <arm_group_label>Perceval S Aortic Heart Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the Perceval S Aortic Heart Valve</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Perceval S Aortic Heart Valve</intervention_name>
    <description>Perceval S Sutureless Aortic Heart Valve</description>
    <arm_group_label>Perceval S Aortic Heart Valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Subjects of age &gt;= 18 years.

          2. Subjects with aortic valve stenosis or steno-insufficiency.

          3. The subject is willing to sign the informed consent.

          4. The subject in which preoperative evaluation indicated the need for native or
             prosthetic aortic valve replacement.

          5. The subject is located in a geographic location that will enable the subject to
             return to the study site for all follow-up examinations (i.e. geographically stable).

          6. Subject will be available to the investigator(s) for postoperative follow-up beyond
             one year.

        Exclusion criteria:

          1. The subject has preexisting valve prosthesis or annuloplasty ring in the mitral,
             pulmonic or tricuspid position.

          2. The subject requires a double or multiple valve replacement or repair of the mitral,
             tricuspid, or pulmonic valve.

          3. The subject has a previously implanted PERCEVAL valve that requires replacement.

          4. Subjects requiring simultaneous cardiac procedures, apart from septal myectomy and/or
             coronary by-pass.

          5. The subject has active endocarditis.

          6. Subjects with active myocarditis

          7. The subject is or will be participating in a concomitant research study of an
             investigational product.

          8. Subjects with aneurysmal dilation or dissection of the ascending aortic wall.

          9. The subject is a minor, drug abuser, alcohol abuser, prison inmate,
             institutionalized, or is unable to give informed consent.

         10. The subject has a major or progressive non-cardiac disease that, in the
             investigator's experience, results in a life expectancy of less than 1 year, or the
             implant of the device produces an unacceptable increased risk to the patient.

         11. Subjects with known hypersensitivity to nickel alloys.

         12. The subject is undergoing renal dialysis for chronic renal failure or has
             hyperparathyroidism.

         13. The subject has had an acute preoperative neurological deficit, myocardial
             infarction, or cardiac event that has not returned to baseline or stabilized â‰¥30 days
             prior to the planned valve implant surgery.

         14. Subject is known to be noncompliant or is unlikely to complete the study.

         15. Subjects with an aortic root enlargement, where the ratio between the diameter of the
             sino-tubular junction and the annulus diameter, assessed by TTE, is &gt; 1.3.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rakesh Suri, MD, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic- Rochester, MN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie T Steinbrink, MA</last_name>
    <phone>651-329-0351</phone>
    <email>marie.steinbrink@sorin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheri L Halverson, MPH</last_name>
    <phone>720-369-7633</phone>
    <email>sheri.halverson@sorin.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Miller, RN</last_name>
      <phone>205-975-3525</phone>
      <email>kath@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Louis A Brunsting III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mick De Robertis, RN</last_name>
      <phone>310-423-5621</phone>
      <email>derobertism@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Alfredo Trento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Baio, RN</last_name>
      <email>kbaio@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Vinod Thourani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Barnett, RN</last_name>
      <phone>317-583-7804</phone>
      <email>lisa.barnett@stvincent.org</email>
    </contact>
    <investigator>
      <last_name>David Heimansohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Munsey</last_name>
      <phone>313-436-2439</phone>
      <email>Barbara.Munsey@oakwood.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Rolbiecki, BSN</last_name>
      <phone>507-255-5027</phone>
      <email>rolbiecki.deborah@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Rakesh Suri, MD, DPhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center/Albert Einstein College of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Swayze, RN, MBA/HCM</last_name>
      <phone>718-920-2221</phone>
      <email>RSWAYZE@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Robert Michler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NSLIJ</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Lucca-Susana</last_name>
      <phone>212-434-3734</phone>
      <email>Mluccasusa@NSHS.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory P Fontana, MD, FACS, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robbi Palumbo, RN</last_name>
      <phone>216-444-8774</phone>
      <email>palumbr@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Eric Roselli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vickie Snyder, RN, CCRC</last_name>
      <phone>419-291-3649</phone>
      <email>vickie.snyder@promedica.org</email>
    </contact>
    <investigator>
      <last_name>Michael Moront, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic and Vascluar Surgeons</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Johnson, MT, CCRC</last_name>
      <phone>512-651-8403</phone>
      <email>DONNA@ctvstexas.com</email>
    </contact>
    <investigator>
      <last_name>William Kessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Burks, RN, CCRC</last_name>
      <phone>434-243-0315</phone>
      <email>SGB2C@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Gorav Ailawadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Martin</last_name>
      <phone>703-776-7071</phone>
      <email>lisa.martin@inova.org</email>
    </contact>
    <investigator>
      <last_name>Niv Ad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Garcia</last_name>
      <phone>206-897-5916</phone>
      <email>igarc@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Gabriel Aldea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic valve replacement</keyword>
  <keyword>aortic stenosis</keyword>
  <keyword>aortic steno-insufficiency</keyword>
  <keyword>Perceval</keyword>
  <keyword>Sutureless aortic heart valve</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
